lu codes
Source: ODB Formulary/CDI, edition 43 (effective 2026-04-28). Checked weekly for updates. Unofficial search tool.
/
10 drugs, 32 codes
GRANISETRON HCL Kytril, Apo-Granisetron, Nat-Granisetron, Jamp Granisetron
For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.
1 year
For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.
1 year
For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics.
1 year
For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.
1 year
The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven.
antiemetics and antinauseants
DIPHENOXYLATE HYDROCHLORIDE & ATROPINE SULFATE, LOPERAMIDE HCL Lomotil, Imodium, Teva-Loperamide, Apo-Loperamide, PMS-Loperamide
An ileostomy or a colostomy;.
1 year
Bowel resection, including short bowel syndrome;
1 year
Inflammatory Bowel Diseases, i.e. Crohn's Disease and Ulcerative Colitis;
1 year
Cancer, including chemotherapy or radiation therapy;
1 year
HIV/AIDS;
1 year
Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care;
1 year
Fecal incontinence.
1 year
antidiarrhea agents
LIPASE & AMYLASE & PROTEASE, PANCRELIPASE EQUIVALENT TO LIPASE & AMYLASE & PROTEASE Creon Minimicrospheres 35, Cotazym, Cotazym ECS 8, Cotazym ECS 20, Pancrease MT4, Creon 10 +3 more
Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).
Indefinite
Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.
Indefinite
Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.
Indefinite
Replacement therapy for pancreatic insufficiency due to cystic fibrosis.
Indefinite
digestants
ONDANSETRON HYDROCHLORIDE Zofran ODT (Tablet), Ondissolve ODF (Film), Ondansetron ODT (Tablet), Mint-Ondansetron ODT (Tablet), Auro-Ondansetron ODT (Tablet), Mar-Ondansetron ODT Tablet +18 more
For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.
1 year
For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.
1 year
For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics.
1 year
For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.
1 year
The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven.
For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics.
1 year
Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.
antiemetics and antinauseants
LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE SODIUM Prevacid, Teva-Lansoprazole, Apo-Lansoprazole, Mylan-Lansoprazole, Lansoprazole, Sandoz Lansoprazole +32 more
Gastroesophageal Reflux Disease (GERD)
1 year
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
1 year
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Other Gastrointestinal Disorders:
1 year
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Severe Conditions:
1 year
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
miscellaneous g.i. drugs
LANSOPRAZOLE, OMEPRAZOLE MAGNESIUM, PANTOPRAZOLE SODIUM Prevacid, Teva-Lansoprazole, Apo-Lansoprazole, Mylan-Lansoprazole, Lansoprazole, Sandoz Lansoprazole +24 more
H. pylori-positive Peptic Ulcers
1 year
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
miscellaneous g.i. drugs
LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN Hp-PAC, AA-LansoprazoleAmoxicillinClarithromycin
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a course of up to 14 days.
1 year
Maximum duration: 14 days.
For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a course of up to 14 days.
1 year
Maximum duration: 14 days (after a four-week period has elapsed since the end of the previous treatment)
Retreatment decisions should be based upon positive symptoms and positive endoscopy or positive urea breath test. Retreatment should not be based on a positive serology test, as serology tests may remain positive indefinitely. An alternative antibiotic regimen is recommended when initial therapy fails due to concerns of antimicrobial resistance.
miscellaneous g.i. drugs
APREPITANT Emend Tri-Pack
In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens:
1 year
- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared
- Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared
- Cisplatin (any dose) given for 3 to 5 consecutive days
- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)
Dosage: Recommend aprepitant 125mg orally on Day 1 of HEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.
1 year
Dosage: Recommend aprepitant 125mg orally on Day 1 of MEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
antiemetics and antinauseants
GRANISETRON HCL, ONDANSETRON HYDROCHLORIDE Kytril, Apo-Granisetron, Nat-Granisetron, Jamp Granisetron, Zofran ODT (Tablet), Ondissolve ODF (Film) +22 more
For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.
1 year
antiemetics and antinauseants
NETUPITANT & PALONOSETRON HYDROCHLORIDE Akynzeo
In combination with dexamethasone for once per-cycle treatment in adult patients for:
1 year
- Prevention of acute and delayed nausea and vomting associated with highly emetogenic cancer chemotherapy (HEC).
Highly emetogenic chemotherapy (HEC) regimens:
- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70mg per meter squared
- Cisplatin and cyclophosphamide combinations where the single daily dose of cisplatin is greater than or equal to 50mg per meter squared
- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide).
Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each HEC.
In combination with dexamethasone for once per-cycle treatment in adult patients for:
1 year
- Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy (MEC) that is uncontrolled by a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) alone in a previous cycle.
Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each MEC cycle.
antiemetics and antinauseants
No matching LU codes found.